Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bucillamine - Revive Therapeutics

Drug Profile

Bucillamine - Revive Therapeutics

Alternative Names: REV-002; REV-004; REV-005

Latest Information Update: 15 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Revive Therapeutics
  • Class Antivirals; Cysteines; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Antioxidants; Chelating agents; Immunomodulators; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinuria
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Cystinuria; Gout
  • No development reported Hepatolenticular degeneration

Most Recent Events

  • 30 Sep 2020 Phase-III clinical trials in COVID-2019 infections in USA (PO) (NCT04504734)
  • 29 Sep 2020 Revive Therapeutics plans a phase III trial for COVID-2019 infections in USA, Canada and Asia-pacific countries (PO, Tablet) in October 2020 (NCT04504734)
  • 16 Sep 2020 The independent Institutional Review Board (IRB) approves an expanded access protocol (EAP) for compassionate use of bucillamine for COVID-2019 infections in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top